Celgene European Panel Recommends Against Revlimid for MDS

NEW YORK, Jan 24 (Reuters) - Celgene Corp said on Thursday an advisory panel for European health regulators recommended Revlimid not be approved in Europe for myelodysplastic syndrome patients with anemia, citing safety concerns.
MORE ON THIS TOPIC